Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab OLE in Ankylosing Spondylitis
NCT03355573Phase 2Completed
- Sponsor
- UCB
- Start
- Nov 2017
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of bimekizumab in ankylosing spondylitis (AS), sponsored by UCB. Started Nov 2017; status: completed.
02
Drugs
bimekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT03355573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03355573.